1-3 of 3
Yingqing Sun
Close
Sort by
Journal Articles

Preclinical Development of an Anti-CD38 Antibody-Drug Conjugate for Treatment of Hematological Malignancies

Lingna Li, PhD, Wenyong Tong, PhD, Megan Lau, BS, Katherine Fells, PhD, Tong Zhu, PhD, Yingqing Sun, PhD, Ernest Kovacs, PhD, Alisher Khasanov, PhD, Zheng Yan, PhD, Dalun Deng, PhD, Ken Takeshita, MD, Gunnar F. Kaufmann, PhD, Henry Ji, PhD, Hui Li, PhD, Hong Zhang, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5621.
https://doi.org/10.1182/blood-2019-132062
Published: 2019
Journal Articles

Preclinical Development of a Bcma Targeting Antibody-Drug Conjugate with Novel Payload for Multiple Myeloma Therapy

Andrew Hau, PhD, Tong Zhu, PhD, Rengang Wang, PhD, Megan Lau, BS, Lingna Li, PhD, Xiaoqing Li, PhD, Yingqing Sun, PhD, Ernest Kovacs, PhD, Alisher Khasanov, PhD, Dalun Deng, PhD, Zheng Yan, PhD, Robert D. Knight, MD, Gunnar F. Kaufmann, PhD, Henry Ji, PhD, Hui Li, PhD, Hong Zhang, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5623.
https://doi.org/10.1182/blood-2019-132080
Published: 2019
Journal Articles

Targeting Hepcidin with Antisense Oligonucletides Improves Anemia Endpoints in Mice.

Jeffrey R. Crosby, PhD, William A. Gaarde, Jarrett Egerston, Robert McKay, Yingqing Sun, Susan Freier, Ph.D., Andy Watt, Gene P. Hung, MD, Bret P. Monia, PhD
Journal: Blood
Blood (2006) 108 (11): 269.
https://doi.org/10.1182/blood.V108.11.269.269
Published: 2006